Ciclesonide

Clinical data
Other names	(11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione
AHFS/Drugs.com	Monograph
MedlinePlus	a607008
Pregnancy category	AU: B3
Routes of administration	Nasal inhalation
ATC code	R01AD13 (WHO) R03BA08 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only
Identifiers
IUPAC name 2-[(1S, 2S, 4R, 8S, 9S,11S, 12S, 13R)-6-cyclohexyl-11-hydroxy-9, 13-dimethyl-16-oxo-5, 7-dioxapentacyclo [10.8.0.02,9.04, 8.013,18] icosa-14, 17-dien-8-yl]- 2-oxoethyl 2-methylpropanoate
CAS Number	126544-47-6 N
PubChem CID	6918155
IUPHAR/BPS	7469
DrugBank	DB01410 Y
ChemSpider	5293368 Y
UNII	S59502J185
KEGG	D01703 Y
ChEMBL	ChEMBL1201164 N
CompTox Dashboard (EPA)	DTXSID9046659
ECHA InfoCard	100.210.908
Chemical and physical data
Formula	C32H44O7
Molar mass	540.697 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(OCC(=O)[C@]25O[C@@H](O[C@@H]5C[C@H]1[C@H]4[C@H]([C@@H](O)C[C@@]12C)[C@]/3(/C=C\C(=O)\C=C\3CC4)C)C6CCCCC6)C(C)C
InChI InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1 Y Key:LUKZNWIVRBCLON-GXOBDPJESA-N Y
NY (what is this?)  (verify)

Ciclesonide is a glucocorticoid used to treat asthma and allergic rhinitis. It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, Zetonna, and Alvesco^[1] for hay fever in the US and Canada.

Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.^[2]

It was patented in 1990 and approved for medical use in 2005.^[3] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.^[4] It is on the World Health Organization's List of Essential Medicines.^[5]